Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Pyruvate:ferredoxin oxidoreductase, which converts pyruvate into acetyl-CoA and CO2 while reducing the ferredoxin. Hydrogenase, which converts H+ into H2 while oxidizing the ferredoxin. Acetyl-CoA synthetase (in reverse), which converts acetyl-CoA and ADP + Pi into acetate, coenzyme A, and ATP. (A variant of the reaction uses acetate:succinate CoA transferase and succinyl-CoA synthatase in reverse.) The net reaction is conversion of singular equivalents of pyruvate, ADP, and Pi into ATP, CO2, acetate, and H2.
This meeting had been approved at the highest levels of both governments because each side had something the other wanted very badly: the Soviets wanted to know exactly why Boeing had put the 747 engines in under-wing pods instead of at the rear of the fuselage, while Withington and the Boeing engineers had a long list of questions about the processing and use of titanium in airframes (at the time Boeing badly needed this for their proposed Boeing 2707 SST, at Mach 3 too fast and hot for Concorde-style aluminium, and the Soviets then led the world in titanium technology). According to Sutter's account, both sides left the meeting well satisfied with the exchange of information. It seems (again according to Sutter's account of the aftermath) that this meeting may have made a real difference to Soviet aircraft design, but Boeing's contribution could naturally not be acknowledged publicly by the Soviet side. Ilyushin therefore had to stress that it had been the first in the world to use podded engines suspended from pylons beneath and ahead of the wing, on the experimental Ilyushin Il-22 four-engined jet bomber of 1946 (first use of this designation). Having thus presented the Il-86's ultimate configuration as indigenously Soviet, the bureau could at last show it in public in 1973, six years after publication of the aerobus specification and four years after the design assignment. A modern six-window flightdeck followed, in place of the 18-to-20 window glazing of the Il-18, Il-62 and Il-76. The main problem facing the Il-86 project was the lack of a suitable engine.
The protein component of AGPs is rich in the amino acids Proline (P), Alanine (A), Serine (S) and Threonine (T), also known as 'PAST', and this amino acid bias is one of the features used to identify them. AGPs are intrinsically disordered proteins as they contain a high proportion of disordering amino acids such as Proline that disrupt the formation of stable folded structures. Characteristic of intrinsically disordered proteins, AGPs also contain repeat motifs and post-translational modifications. Proline residues in the protein backbone can be hydroxylated to Hydroxyproline (O) depending on the surrounding amino acids. The 'Hyp contiguity hypothesis' predicts that when O occurs in a non-contiguous manner, for example the sequence 'SOTO', such as occurs in AGPs, this acts as a signal for O-linked glycosylation of large branched type II arabinogalactan (AG) polysaccharides. Sequences that direct AG glycosylation (SO, TO, AO, VO) are called AGP glycomotifs. All AGP protein backbones contain a minimum of 3 clustered AGP glycomotifs and an N-terminal signal peptide that directs the protein into the endoplasmic reticulum (ER) where post-translational modifications begin. Prolyl hydroxylation of P to O is fulfilled by prolyl 4-hydroxylases (P4Hs) belonging to the 2-oxoglutarate dependant dioxygenase family. P4H has been identified in both the ER and Golgi apparatus. The addition of the glycosylphosphatidylinositol (GPI)-anchor occurs in most but not all AGPs.
They further demonstrated that increased hepatic acetyl-CoA and glycerol flux—resulting from white adipose tissue inflammation—are key drivers of elevated gluconeogenesis in rodent models of type 2 diabetes (T2D). Based on the sn-1,2 DAG–nPKC hypothesis, Shulman's laboratory developed liver-targeted mitochondrial protonophores that reduce hepatic steatosis, insulin resistance, inflammation, and fibrosis in rodent and nonhuman primate models of MASLD and MASH. These compounds have advanced to clinical evaluation.
== Voting == OECD decisions are made through voting, which requires unanimity among all of those voting. Each member country has one vote. However, dissenting members which do not wish to block a decision but merely to signal their disapproval can abstain from voting. 22 of the OECD member countries are also EU member states.
Sources: en.wikipedia.org
== Clinical significance == Reactive electrophiles produced by oxidative metabolism have been linked to a number of degenerative diseases including Parkinson's disease, Alzheimer's disease, cataract formation, and atherosclerosis hence reduced expression of the GSTA4 enzyme may have pathophysiological consequences. The expression of this gene is decreased drastically among burn and trauma victims.
==== Allergic conditions ==== Setipiprant binds to the DP2 receptor with a dissociation constant of 6 nM, representing potent antagonism of the receptor. The DP2 receptor, also called the CRTh2 receptor, is a G-protein-coupled receptor (GPCR) that is expressed on certain inflammatory cells, such as eosinophils, basophils, and certain lymphocytes. For its mechanism of action in the treatment of allergic conditions, setipiprant's DP2 antagonism prevents the action of prostaglandin D2 (PGD2) on these receptors. The DP2 receptor mediates the activation of type 2 helper T (Th2) cells, eosinophils, and basophils in the lungs, which are white blood cells implicated in producing the inflammatory response the characterizes allergic conditions. Activation of DP2 on Th2 cells by PGD2 induces the secretion of inflammatory cytokines (interleukin (IL) 4, IL-5, and IL-13), which cause an increase of eosinophils in the blood, remodeling of lung tissue, and hypersensitivity of lung tissue to allergens. Setipiprant does not antagonize the thromboxane receptor (TP). The bronchoconstricting properties of PGD2 are not inhibited by setipiprant, since these are mediated by the TP receptor. As a point of contrast, ramatroban is a selective TP antagonist and DP2 receptor antagonist. Setipiprant does not appreciably inhibit the activity of the enzyme cyclooxygenase 1 (COX-1), which is responsible for the synthesis of prostaglandins (including PGD2).
Chick-fil-A has donated over $5 million, via the WinShape Foundation, to groups that oppose same-sex marriage. In response, students at several colleges and universities worked to ban or remove the company's restaurants from their campuses. In June and July 2012, Chick-fil-A's chief operating officer Dan T. Cathy made several public statements about same-sex marriage, saying that those who "have the audacity to define what marriage is about" were "inviting God's judgment on our nation". Several prominent politicians expressed disapproval. Boston Mayor Thomas Menino and Chicago Alderman Proco "Joe" Moreno said they hoped to block franchise expansion into their areas. The proposed local bans drew criticism from liberal pundits, legal experts, and the American Civil Liberties Union. The Jim Henson Company, which had a Pajanimals kids' meal toy licensing arrangement with Chick-fil-A, said it would cease its business relationship, and donate the payment to the Gay & Lesbian Alliance Against Defamation. Chick-fil-A stopped distributing the toys, claiming that unrelated safety concerns had arisen before the controversy. Chick-fil-A released a statement on July 31, 2012, saying, "We are a restaurant company focused on food, service, and hospitality; our intent is to leave the policy debate over same-sex marriage to the government and political arena." In response to the controversy, former Arkansas Governor Mike Huckabee initiated a Chick-fil-A Appreciation Day movement to counter a boycott of Chick-fil-A launched by same-sex marriage activists.
Open to people of good moral character of Polish, Lithuanian, or Slavic descent and of the Roman Catholic, Byzantine Catholic or Greek Catholic Church or those married to one of the acceptable ethics and a member of the approved churches. Honorary membership is given to those who rendered a great service to the Association, Catholicism, the United States, or mankind in general. The minimum age is 15, though juvenile insurance/membership was available. In 1967 it had 24,500 members in 1979 16,000 in 105 groups. No ritual, but there is an oath. Offers scholarships, organizes folk dances, polka and Halloween parties, etc. Involved with the Catholic church. Patron saint is St. John Cantius, holds Masses and organized a pilgrimage to the National Shrine of Our Lady of Czestochowa in Doylestown, Pennsylvania. Polish Falcons of America Polish National Alliance of Brooklyn - Founded in 1903. Despite the name, it had members and was licensed to sell insurance in Connecticut, Michigan, Minnesota, New Jersey, and New York. Absorbed Polish American Workmen Aid Fund in 1960. Had 21,413 in 1965, approximately 12,000 in 1979 and 11,135 in 1995. Had 155 lodges in 1972, 87 in 1978. Offers Masses to its members, yearly grants to the Catholic Foundation and theological seminaries. Polish National Alliance Polish National Union (Sponjnia - Founded in February 1908 in the parish hall of St. Stanislaus Cathedral, in Scranton, Pennsylvania. Received charter by the end of the year. Women's lodges were authorized in 1909. Had difficulty retaining membership because it was actuarially unsound.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.